Cargando…

Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer

Objective In this study, we aimed to assess the response and toxicity related to dose escalation in external beam radiation therapy (EBRT) using intensity-modulated radiation therapy (IMRT) with weekly concurrent cisplatin followed by de-escalated brachytherapy (BT) in locally advanced carcinoma cer...

Descripción completa

Detalles Bibliográficos
Autores principales: Shewalkar, Balaji, Khan, Asfiya, Yerlekar, Dnyanda, Patel, Jitendra, Khadilkar, Hrishikesh, Sakthivel, Rajakumar, Kataruka, Reeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285639/
https://www.ncbi.nlm.nih.gov/pubmed/35855254
http://dx.doi.org/10.7759/cureus.25965
_version_ 1784747829925773312
author Shewalkar, Balaji
Khan, Asfiya
Yerlekar, Dnyanda
Patel, Jitendra
Khadilkar, Hrishikesh
Sakthivel, Rajakumar
Kataruka, Reeta
author_facet Shewalkar, Balaji
Khan, Asfiya
Yerlekar, Dnyanda
Patel, Jitendra
Khadilkar, Hrishikesh
Sakthivel, Rajakumar
Kataruka, Reeta
author_sort Shewalkar, Balaji
collection PubMed
description Objective In this study, we aimed to assess the response and toxicity related to dose escalation in external beam radiation therapy (EBRT) using intensity-modulated radiation therapy (IMRT) with weekly concurrent cisplatin followed by de-escalated brachytherapy (BT) in locally advanced carcinoma cervix of International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIB-IIIC1. Materials and methods Fifty-two patients diagnosed with cervical cancer FIGO 2018 stage IIB-IIIC1 were treated with curative intent from November 2019 to October 2021. The dose of 50 Gy was prescribed for the primary tumor volume and elective pelvic nodal volume followed by a primary boost to a dose of 20 Gy. Gross lymph node (LN) of size >1 cm after EBRT completion received a sequential nodal boost of 10 Gy. All patients received concurrent cisplatin to a dose of 40 mg/m(2) for a total of five to six weekly cycles. All patients received two fractions of BT to a dose of 6 Gy after EBRT completion. Radiation-induced acute toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) criteria and hematologic toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results A median follow-up of six months was available for the 40 eligible patients. All patients tolerated treatment with an acceptable toxicity profile. Grade III dermatitis, grade III gastrointestinal (GI) toxicity, and grade III genitourinary (GU) toxicity were seen in three (7.5%), six (17.5%), and three patients (7.5%) respectively. Grade I anemia was evident in all patients. At six months after EBRT completion, 37 patients (92.5%) had a complete response and only three patients (7.5%) had residual disease. Conclusion Based on our findings, patients with cervical cancer treated with dose-escalated IMRT have a satisfactory outcome with reasonably low levels of treatment-related acute GI and GU toxicities. The findings of the present study endorse the notion that the application of a high dose of external radiation to the pelvis by IMRT technique with image-guided delivery could be an acceptable alternative to the standard-dose management schedule.
format Online
Article
Text
id pubmed-9285639
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-92856392022-07-18 Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer Shewalkar, Balaji Khan, Asfiya Yerlekar, Dnyanda Patel, Jitendra Khadilkar, Hrishikesh Sakthivel, Rajakumar Kataruka, Reeta Cureus Obstetrics/Gynecology Objective In this study, we aimed to assess the response and toxicity related to dose escalation in external beam radiation therapy (EBRT) using intensity-modulated radiation therapy (IMRT) with weekly concurrent cisplatin followed by de-escalated brachytherapy (BT) in locally advanced carcinoma cervix of International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIB-IIIC1. Materials and methods Fifty-two patients diagnosed with cervical cancer FIGO 2018 stage IIB-IIIC1 were treated with curative intent from November 2019 to October 2021. The dose of 50 Gy was prescribed for the primary tumor volume and elective pelvic nodal volume followed by a primary boost to a dose of 20 Gy. Gross lymph node (LN) of size >1 cm after EBRT completion received a sequential nodal boost of 10 Gy. All patients received concurrent cisplatin to a dose of 40 mg/m(2) for a total of five to six weekly cycles. All patients received two fractions of BT to a dose of 6 Gy after EBRT completion. Radiation-induced acute toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) criteria and hematologic toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results A median follow-up of six months was available for the 40 eligible patients. All patients tolerated treatment with an acceptable toxicity profile. Grade III dermatitis, grade III gastrointestinal (GI) toxicity, and grade III genitourinary (GU) toxicity were seen in three (7.5%), six (17.5%), and three patients (7.5%) respectively. Grade I anemia was evident in all patients. At six months after EBRT completion, 37 patients (92.5%) had a complete response and only three patients (7.5%) had residual disease. Conclusion Based on our findings, patients with cervical cancer treated with dose-escalated IMRT have a satisfactory outcome with reasonably low levels of treatment-related acute GI and GU toxicities. The findings of the present study endorse the notion that the application of a high dose of external radiation to the pelvis by IMRT technique with image-guided delivery could be an acceptable alternative to the standard-dose management schedule. Cureus 2022-06-15 /pmc/articles/PMC9285639/ /pubmed/35855254 http://dx.doi.org/10.7759/cureus.25965 Text en Copyright © 2022, Shewalkar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Obstetrics/Gynecology
Shewalkar, Balaji
Khan, Asfiya
Yerlekar, Dnyanda
Patel, Jitendra
Khadilkar, Hrishikesh
Sakthivel, Rajakumar
Kataruka, Reeta
Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title_full Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title_fullStr Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title_full_unstemmed Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title_short Dose-Escalated Intensity-Modulated Radiotherapy for the Management of Locally Advanced Cervical Cancer
title_sort dose-escalated intensity-modulated radiotherapy for the management of locally advanced cervical cancer
topic Obstetrics/Gynecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285639/
https://www.ncbi.nlm.nih.gov/pubmed/35855254
http://dx.doi.org/10.7759/cureus.25965
work_keys_str_mv AT shewalkarbalaji doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT khanasfiya doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT yerlekardnyanda doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT pateljitendra doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT khadilkarhrishikesh doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT sakthivelrajakumar doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer
AT katarukareeta doseescalatedintensitymodulatedradiotherapyforthemanagementoflocallyadvancedcervicalcancer